PMID- 26629085
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20151202
LR  - 20200929
IS  - 1940-5901 (Print)
IS  - 1940-5901 (Electronic)
IS  - 1940-5901 (Linking)
VI  - 8
IP  - 9
DP  - 2015
TI  - Therapeutic effects of bone marrow mesenchymal stem cells expressing 
      interleukin-12 in mice bearing malignant ascites tumor.
PG  - 15840-5
AB  - This study is to investigate the therapeutic effects of bone marrow mesenchymal 
      stem cells (BMSCs) expressing interleukin (IL)-12 on malignant ascites 
      tumor-bearing mice and the related mechanisms. Malignant ascites tumor mouse 
      model was established by the intraperitoneal inoculation with MethA or H22 tumor 
      cells. Mouse BMSCs were transfected with lentiviral vector containing IL-12, and 
      then transplanted into these mouse models via intraperitoneal injection. The 
      peritoneal permeability in these mice was evaluated and compared. The contents of 
      INF-gamma and VEGF in ascites were determined by ELISA. Mouse models receiving 
      IL-12-expressing BMSCs were rechallenged with tumor cells, and the animal 
      survival was observed and analyzed. In both MethA and H22 tumor cell-induced 
      malignant ascites tumor mouse models, there were no significant differences in 
      the peritoneal permeability between the normal saline (NS), BMSC-control, and 
      BMSC-null groups. However, compared with NS control group, the peritoneal 
      permeability was significantly decreased by IL-12-expressing BMSCs. Moreover, 
      ELISA showed that, in both the MethA and H22 tumor cell-induced mouse models, 
      compared with the NS control group, the contents of INF-gamma in ascites were 
      significantly elevated, while the contents of VEGF in ascites were significantly 
      decreased, in the BMSC-IL-12 groups. In addition, IL-12-expressing BMSCs 
      significantly elongated the survival of mouse models after rechallenging with 
      tumor cells. IL-12-expressing BMSCs exert protective effects against malignant 
      ascites tumor, and the anti-tumor effects might be associated with the enhanced 
      anti-tumor immunity. Our findings might bring new insights into the treatment of 
      tumors with immunotherapy.
FAU - Wang, Aihong
AU  - Wang A
AD  - School of Medicine, Yan'an University Yan'an 716000, Shaanxi, China.
FAU - Zhou, Xiaoyan
AU  - Zhou X
AD  - School of Medicine, Yan'an University Yan'an 716000, Shaanxi, China.
FAU - Zhao, Jumei
AU  - Zhao J
AD  - School of Medicine, Yan'an University Yan'an 716000, Shaanxi, China.
FAU - Liu, Tao
AU  - Liu T
AD  - Department of Otolaryngology, The Affiliated Hospital of Yan'an University Yan'an 
      716000, Shaanxi, China.
FAU - Xu, Jianrong
AU  - Xu J
AD  - School of Life Science, Southwest University of Science and Technology Mianyang 
      621010, Sichuan, China ; State Key Laboratory of Biotherapy, West China Hospital, 
      Sichuan University Chengdu 610041, Sichuan, China.
LA  - eng
PT  - Journal Article
DEP - 20150915
PL  - United States
TA  - Int J Clin Exp Med
JT  - International journal of clinical and experimental medicine
JID - 101471010
PMC - PMC4658974
OTO - NOTNLM
OT  - Bone marrow mesenchymal stem cells (BMSCs)
OT  - immunotherapy
OT  - interleukin (IL)-12
OT  - malignant ascites tumor
EDAT- 2015/12/03 06:00
MHDA- 2015/12/03 06:01
PMCR- 2015/09/15
CRDT- 2015/12/03 06:00
PHST- 2015/05/26 00:00 [received]
PHST- 2015/08/28 00:00 [accepted]
PHST- 2015/12/03 06:00 [entrez]
PHST- 2015/12/03 06:00 [pubmed]
PHST- 2015/12/03 06:01 [medline]
PHST- 2015/09/15 00:00 [pmc-release]
PST - epublish
SO  - Int J Clin Exp Med. 2015 Sep 15;8(9):15840-5. eCollection 2015.